SELECTing adjuvant treatment in early stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer

Benzer Materyaller

• Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
  Yazar:: Tabbò, Fabrizio, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Changing paradigms of non-small cell lung cancer treatment
  Yazar:: Guerrera, Francesco, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer
  Yazar:: Tabbò, Fabrizio, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations
  Yazar:: Bironzo, Paolo, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• VATS lobectomy vs. open lobectomy for early-stage lung cancer: an endless question—are we close to a definite answer?
  Yazar:: Guerrera, Francesco, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)